Clinical Trial Update: Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a multi-drug regimen (doxorubicin hydrochloride, cyclophosphamide, filgrastim) followed by paclitaxel albumin-stabilized nanoparticle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound) (paclitaxel albumin-bound)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)
• Filgrastim (filgrastim)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: University of Washington | Conditions: Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-08-31